Pfizer’s Abrysvo Is First RSV Vaccine Approved For Younger High-Risk Adults
Pfizer beat GSK with a new indication for its RSV vaccine in high-risk individuals aged 18-59.

Pfizer beat GSK with a new indication for its RSV vaccine in high-risk individuals aged 18-59.